Teva Pharmaceutical Industries did not meet the primary endpoint of its Phase II trial to evaluate the efficacy, safety and tolerability of Talampanel, a drug that reduces disease-related functional deterioration in amyotrophic lateral sclerosis (ALS) patients.
The study results indicate the drug is safe but did not meet the efficacy requirements.
The double-blind, multicentre, multinational, randomised study was conducted in 25 sites across Canada, Israel, Europe and the US, involving 559 patients with ALS.
Also known as Lou Gehrig’s disease, ALS is a degenerative motor neuron disease that leads to paralysis and ultimately death within five years from the disease’s onset.
Over 10,000 patients every year are diagnosed with ALS in Europe and the US.